| High-Dose Carboplatin With Diethyldithiocarbamate Chemoprotection in Treatment of Women With Relapsed Ovarian Cancer (1988) | |||||||||||||
Abstract | |||||||||||||
| Diethyldithiocarbamate (DDTC) has been found to protect the bone marrow, kidneys, and gastrointestinal tract, from the toxic effects of cisplatin and carboplatin (CBDCA) in animal mod-1 els. In an attempt to minimize the { toxic effects of high-dose CBDCA (800 mg/m2), a pilot study was undertaken in which women with relapsed or re-, fractory epithelial ovarian cancer were s treated with high-dose CBDCA, which was followed 3 hours later with DDTC (4 g/m). There were four partial responses and no complete response in 21 patients who could be evalu-, ated (overall response rate, 19%). Significant toxic effects, including three ; treatment-related deaths, were associ-'. ated with the regimen. This study suggests that while high-dose CBDCA plus 1 DDTC may be active in relapsed or j refractory ovarian cancer, it is associated with clinically significant hema-tologic and autonomic toxic effects. [J Natl Cancer Inst 1988;80:1488–1492] | |||||||||||||
Publication details | |||||||||||||
| |||||||||||||